Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD of Foghorn Therapeutics Inc. from Q1 2022 to Q4 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Foghorn Therapeutics Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2022 to Q4 2024.
- Foghorn Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending December 31, 2024 was -$19.5M, a 11.8% increase year-over-year.
- Foghorn Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending December 31, 2024 was -$86.6M, a 8.05% increase year-over-year.
- Foghorn Therapeutics Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was -$86.6M, a 8.05% increase from 2023.
- Foghorn Therapeutics Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$94.2M, a 13.5% increase from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)